

# Joan B Soriano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2269977/publications.pdf>

Version: 2024-02-01

375  
papers

69,551  
citations

3525

90  
h-index

735

251  
g-index

415  
all docs

415  
docs citations

415  
times ranked

82251  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
2	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	6.3	5,298
3	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	6.3	4,989
4	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	6.3	4,934
5	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1151-1210.	6.3	3,565
6	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	6.3	3,269
7	Alcohol use and burden for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 392, 1015-1035.	6.3	2,005
8	Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 691-706.	5.2	1,672
9	Smoking prevalence and attributable disease burden in 195 countries and territories, 1990â€“2015: a systematic analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 389, 1885-1906.	6.3	1,281
10	A clinical case definition of post-COVID-19 condition by a Delphi consensus. <i>Lancet Infectious Diseases, The</i> , 2022, 22, e102-e107.	4.6	1,068
11	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 56-87.	4.9	1,064
12	Prevalence and attributable health burden of chronic respiratory diseases, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 585-596.	5.2	1,049
13	Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2015, 373, 111-122.	13.9	974
14	Mortality in COPD: role of comorbidities. <i>European Respiratory Journal</i> , 2006, 28, 1245-1257.	3.1	864
15	Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. <i>European Respiratory Journal</i> , 2000, 16, 802-807.	3.1	858
16	Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 40-47.	1.5	789
17	Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1775-1812.	6.3	740
18	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	6.3	716

#	ARTICLE	IF	CITATIONS
19	Global burden of <sc>COPD</sc>. <i>Respirology</i> , 2016, 21, 14-23.	1.3	654
20	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
21	Epidemiology and costs of chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2006, 27, 188-207.	3.1	606
22	Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 325-331.	2.5	589
23	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150.	6.3	573
24	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	6.3	571
25	Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. <i>Thorax</i> , 2009, 64, 863-868.	2.7	537
26	Patterns of Comorbidities in Newly Diagnosed COPD and Asthma in Primary Care. <i>Chest</i> , 2005, 128, 2099-2107.	0.4	518
27	The Natural History of Chronic Airflow Obstruction Revisited. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 3-10.	2.5	516
28	Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. <i>European Respiratory Journal</i> , 2002, 20, 799-805.	3.1	487
29	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	6.3	480
30	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. <i>Lancet HIV,the</i> , 2016, 3, e361-e387.	2.1	461
31	Factors Associated With Lung Function Decline in Adult Patients With Stable Non-Cystic Fibrosis Bronchiectasis. <i>Chest</i> , 2007, 132, 1565-1572.	0.4	423
32	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	6.3	413
33	GuÃ±a espaÃ±ola de la enfermedad pulmonar obstructiva crÃ³nica (GesEPOC) 2017. Tratamiento farmacolÃ³gico en fase estable. <i>Archivos De Bronconeumologia</i> , 2017, 53, 324-335.	0.4	365
34	C-reactive protein in patients with COPD, control smokers and non-smokers. <i>Thorax</i> , 2005, 61, 23-28.	2.7	349
35	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
36	Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. <i>Lancet Respiratory Medicine,the</i> , 2019, 7, 69-89.	5.2	326

#	ARTICLE	IF	CITATIONS
37	Determinants of Underdiagnosis of COPD in National and International Surveys. <i>Chest</i> , 2015, 148, 971-985.	0.4	316
38	Screening for and early detection of chronic obstructive pulmonary disease. <i>Lancet, The</i> , 2009, 374, 721-732.	6.3	303
39	The Proportional Venn Diagram of Obstructive Lung Disease*. <i>Chest</i> , 2003, 124, 474-481.	0.4	302
40	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	6.3	294
41	What is asthmaâ€™COPD overlap syndrome? Towards a consensus definition from a round table discussion. <i>European Respiratory Journal</i> , 2016, 48, 664-673.	3.1	287
42	Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. <i>European Respiratory Journal</i> , 2002, 20, 819-825.	3.1	266
43	Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. <i>Thorax</i> , 2005, 60, 992-997.	2.7	253
44	Asthma control in the Asia-Pacific region: The asthma insights and reality in Asia-Pacific study. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 263-268.	1.5	251
45	Recent trends in physician diagnosed COPD in women and men in the UK. <i>Thorax</i> , 2000, 55, 789-794.	2.7	239
46	GuÃa EspaÃola de la EPOC (GesEPOC). Tratamiento farmacolÃ³gico de la EPOC estable. <i>Archivos De Bronconeumologia</i> , 2012, 48, 247-257.	0.4	238
47	Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. <i>Chest</i> , 2016, 149, 45-52.	0.4	227
48	Housing characteristics, reported mold exposure, and asthma in the European Community Respiratory Health Survey. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 110, 285-292.	1.5	225
49	What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. <i>European Respiratory Journal</i> , 2003, 22, 809-814.	3.1	218
50	COPD as a Systemic Disease. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2008, 5, 133-138.	0.7	204
51	Comorbidities and Short-term Prognosis in Patients Hospitalized for Acute Exacerbation of COPD. <i>Chest</i> , 2012, 142, 1126-1133.	0.4	204
52	Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. <i>Respiratory Research</i> , 2010, 11, 63.	1.4	199
53	Proportional classifications of COPD phenotypes. <i>Thorax</i> , 2008, 63, 761-767.	2.7	192
54	Documento de consenso sobre el fenotipo mixto EPOC-asma en la EPOC. <i>Archivos De Bronconeumologia</i> , 2012, 48, 331-337.	0.4	192

#	ARTICLE	IF	CITATIONS
55	Characterisation of the overlap COPD&#x201c;asthma phenotype. Focus on physical activity and health status. <i>Respiratory Medicine</i> , 2013, 107, 1053-1060.	1.3	189
56	The risk of asthma attributable to occupational exposures. A population-based study in Spain. Spanish Group of the European Asthma Study.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996, 154, 137-143.	2.5	177
57	Operational definitions of asthma in studies on its aetiology. <i>European Respiratory Journal</i> , 2005, 26, 28-35.	3.1	176
58	Consensus Document on the Overlap Phenotype COPD&#x201c;Asthma in COPD. <i>Archivos De Bronconeumologia</i> , 2012, 48, 331-337.	0.4	176
59	COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes. <i>Journal of Clinical Investigation</i> , 2020, 130, 6290-6300.	3.9	168
60	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, e4-e27.	2.5	166
61	IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 72-80.e8.	1.5	166
62	Variation in bronchial responsiveness in the European Community Respiratory Health Survey (ECRHS). <i>European Respiratory Journal</i> , 1997, 10, 2495-2501.	3.1	165
63	The impact of COVID-19 on patients with asthma. <i>European Respiratory Journal</i> , 2021, 57, 2003142.	3.1	164
64	Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. <i>European Respiratory Journal</i> , 2013, 41, 1252-1256.	3.1	162
65	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , 2019, 574, 353-358.	13.7	161
66	Total serum IgE is associated with asthma independently of specific IgE levels. <i>European Respiratory Journal</i> , 1996, 9, 1880-1884.	3.1	156
67	Asthma control and differences in management practices across seven European countries. <i>Respiratory Medicine</i> , 2002, 96, 142-149.	1.3	146
68	Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997-2007. <i>European Respiratory Journal</i> , 2010, 36, 758-765.	3.1	145
69	GuÃa espaÃola de la EPOC (GesEPOC). ActualizaciÃn 2014. <i>Archivos De Bronconeumologia</i> , 2014, 50, 1-16.	0.4	143
70	Insulin resistance and daytime sleepiness in patients with sleep apnoea. <i>Thorax</i> , 2008, 63, 946-950.	2.7	141
71	Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2005, 17, 191-7.	0.6	140
72	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015, 45, 879-905.	3.1	138

#	ARTICLE	IF	CITATIONS
73	Gender differences in the management and experience of Chronic Obstructive Pulmonary Disease. <i>Respiratory Medicine</i> , 2004, 98, 1207-1213.	1.3	133
74	Spanish Guideline for COPD (GesEPOC). Update 2014. <i>Archivos De Bronconeumologia</i> , 2014, 50, 1-16.	0.4	130
75	Mortality trends in chronic obstructive pulmonary disease in Europe, 1994–2010: a joinpoint regression analysis. <i>Lancet Respiratory Medicine</i> , 2014, 2, 54-62.	5.2	126
76	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. <i>Lancet Respiratory Medicine</i> , 2015, 3, 443-450.	5.2	125
77	Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. <i>European Respiratory Journal</i> , 2017, 50, 1701162.	3.1	122
78	A Pooled Analysis of FEV 1 Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo. <i>Chest</i> , 2007, 131, 682-689.	0.4	121
79	Distribution and Prognostic Validity of the New Global Initiative for Chronic Obstructive Lung Disease Grading Classification. <i>Chest</i> , 2013, 143, 694-702.	0.4	120
80	Short- and Medium-term Prognosis in Patients Hospitalized for COPD Exacerbation. <i>Chest</i> , 2014, 145, 972-980.	0.4	117
81	Prediction of risk of COPD exacerbations by the BODE index. <i>Respiratory Medicine</i> , 2009, 103, 373-378.	1.3	116
82	Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. <i>Thorax</i> , 2018, 73, 116-124.	2.7	116
83	A home telehealth program for patients with severe COPD: The PROMETE study. <i>Respiratory Medicine</i> , 2014, 108, 453-462.	1.3	115
84	Comorbidity, Pattern, and Impact of Asthma-COPD Overlap Syndrome in Real Life. <i>Chest</i> , 2016, 149, 1011-1020.	0.4	113
85	La carga de enfermedad en España: resultados del Estudio de la Carga Global de las Enfermedades 2016. <i>Medicina Clínica</i> , 2018, 151, 171-190.	0.3	113
86	Determinants and impact of suboptimal asthma control in Europe: The INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study. <i>Respiratory Research</i> , 2016, 17, 51.	1.4	110
87	Asthma in the elderly: what we know and what we have yet to know. <i>World Allergy Organization Journal</i> , 2014, 7, 8.	1.6	105
88	Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017. <i>Lancet Infectious Diseases</i> , 2020, 20, 37-59.	4.6	104
89	Prevalence and Determinants of COPD in Spain: EPISCAN II. <i>Archivos De Bronconeumologia</i> , 2021, 57, 61-69.	0.4	103
90	Clinical Characteristics and Prognostic Factors for Intensive Care Unit Admission of Patients With COVID-19: Retrospective Study Using Machine Learning and Natural Language Processing. <i>Journal of Medical Internet Research</i> , 2020, 22, e21801.	2.1	97

#	ARTICLE	IF	CITATIONS
91	Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD. Chest, 2015, 148, 159-168.	0.4	96
92	Inhaled Corticosteroids With/Without Long-Acting $\beta_2$ -Agonists Reduce the Risk of Rehospitalization and Death in COPD Patients. Treatments in Respiratory Medicine, 2003, 2, 67-74.	1.4	93
93	Multicomponent indices to predict survival in COPD: the COCOMICS study. European Respiratory Journal, 2013, 42, 323-332.	3.1	93
94	What is early COPD and why is it important?. European Respiratory Journal, 2018, 52, 1801448.	3.1	90
95	Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. European Journal of Epidemiology, 2001, 17, 1075-1080.	2.5	87
96	Morbidity and mortality from road injuries: results from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i46-i56.	1.2	86
97	Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 19, 57-61.	2.5	84
98	Burden of disease attributable to second-hand smoke exposure: A systematic review. Preventive Medicine, 2019, 129, 105833.	1.6	84
99	European Respiratory Society guidelines for the diagnosis of asthma in adults. European Respiratory Journal, 2022, 60, 2101585.	3.1	84
100	Risk factors for asthma in young adults. European Respiratory Journal, 1997, 10, 2490-2494.	3.1	82
101	High Prevalence of Undiagnosed Airflow Limitation in Patients With Cardiovascular Disease. Chest, 2010, 137, 333-340.	0.4	81
102	Asthma characteristics in cleaning workers, workers in other risk jobs and office workers. European Respiratory Journal, 2002, 20, 679-685.	3.1	78
103	Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respiratory Medicine, 2009, 103, 85-90.	1.3	75
104	Chronic Obstructive Pulmonary Disease Overview: Epidemiology, Risk Factors, and Clinical Presentation. Proceedings of the American Thoracic Society, 2011, 8, 363-367.	3.5	75
105	Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 460-464.	2.5	74
106	Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine, 2004, 98, 1045-1050.	1.3	73
107	Regulation of the cancer cell membrane lipid composition by NaChOleate. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 1619-1627.	1.4	73
108	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Review, 2015, 24, 159-172.	3.0	72



#	ARTICLE	IF	CITATIONS
109	Infradiagnóstico de la enfermedad pulmonar obstructiva crónica en mujeres: cuantificación del problema, determinantes y propuestas de acción. Archivos De Bronconeumología, 2013, 49, 223-229.	0.4	70
110	A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2013, 22, 117-121.	2.5	70
111	Nosocomial Outbreak of <i>Corynebacterium striatum</i> Infection in Patients with Chronic Obstructive Pulmonary Disease. Journal of Clinical Microbiology, 2007, 45, 2064-2067.	1.8	69
112	Recent improvement in long-term survival after a COPD hospitalisation. Thorax, 2010, 65, 298-302.	2.7	69
113	Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 802-812.	2.7	69
114	Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes. Medical Sciences (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.3	68
115	Predictors of Poor Asthma Control in European Adults. Journal of Asthma, 2003, 40, 803-813.	0.9	67
116	COPD case finding by spirometry in high-risk customers of urban community pharmacies: A pilot study. Respiratory Medicine, 2009, 103, 839-845.	1.3	66
117	Number of allergens to be tested to assess allergenic sensitization in epidemiologic studies: results of the European Community Respiratory Health Survey I. Clinical and Experimental Allergy, 2007, 37, 780-787.	1.4	65
118	Asthma control in adults in Asia-Pacific. Respiriology, 2005, 10, 579-586.	1.3	63
119	The Proportional Venn Diagram of Obstructive Lung Disease in the Italian General Population. Chest, 2004, 126, 1093-1101.	0.4	61
120	Telomere shortening in sleep apnea syndrome. Respiratory Medicine, 2010, 104, 1225-1229.	1.3	61
121	Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique. International Journal of COPD, 2018, Volume 13, 57-67.	0.9	60
122	Asthma insights and reality in Turkey (AIRET) study. Respiratory Medicine, 2006, 100, 1850-1854.	1.3	57
123	Overdiagnosing Subjects With COPD Using the 0.7 Fixed Ratio: Correlation With a Poor Health-Related Quality of Life. Chest, 2011, 139, 1072-1080.	0.4	57
124	Prevalence, Risk Factors and Diagnostic Accuracy of COPD Among Smokers in Primary Care. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 404-412.	0.7	57
125	Distribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort. PLoS ONE, 2016, 11, e0160770.	1.1	57
126	COPD patients with and without metabolic syndrome: clinical and functional differences. Internal and Emergency Medicine, 2014, 9, 419-425.	1.0	55



#	ARTICLE	IF	CITATIONS
127	Th-2 signature in chronic airway diseases: towards the extinction of asthmaâ€”COPD overlap syndrome?. <i>European Respiratory Journal</i> , 2017, 49, 1602397.	3.1	55
128	Who Smokes in Europe? Data From 12 European Countries in the TackSHS Survey (2017â€”2018). <i>Journal of Epidemiology</i> , 2021, 31, 145-151.	1.1	55
129	Lung Function Abnormalities in Smokers with Ischemic Heart Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 568-576.	2.5	53
130	A simple algorithm for the identification of clinical COPD phenotypes. <i>European Respiratory Journal</i> , 2017, 50, 1701034.	3.1	53
131	The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group. <i>European Respiratory Journal</i> , 2019, 54, 1901511.	3.1	53
132	Effectiveness of Pulmonary Rehabilitation in Reducing Health Resources Use in Chronic Obstructive Pulmonary Disease. <i>Archives of Physical Medicine and Rehabilitation</i> , 2010, 91, 364-368.	0.5	52
133	Evidence of Gender Differences in the Diagnosis and Management of Coronavirus Disease 2019 Patients: An Analysis of Electronic Health Records Using Natural Language Processing and Machine Learning. <i>Journal of Women's Health</i> , 2021, 30, 393-404.	1.5	52
134	Missense mutations in the cystic fibrosis gene in adult patients with asthma. , 1999, 14, 510-519.		51
135	Characteristics and Prognosis of COVID-19 in Patients with COPD. <i>Journal of Clinical Medicine</i> , 2020, 9, 3259.	1.0	51
136	Smoking habit, respiratory symptoms and lung function in young adults. <i>European Journal of Public Health</i> , 2005, 15, 160-165.	0.1	50
137	Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study. <i>International Journal of COPD</i> , 2017, Volume 12, 417-426.	0.9	50
138	International trends in COPD mortality, 1995â€”2017. <i>European Respiratory Journal</i> , 2019, 54, 1901791.	3.1	50
139	Sex differences between women and men with COPD: A new analysis of the 3CIA study. <i>Respiratory Medicine</i> , 2020, 171, 106105.	1.3	50
140	Impact of Obesity on the Clinical Profile of a Population-Based Sample with Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2014, 9, e105220.	1.1	50
141	Geographic differences in clinical characteristics and management of COPD: the EPOCA study. <i>International Journal of COPD</i> , 2008, Volume 3, 803-814.	0.9	49
142	Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study. <i>International Journal of COPD</i> , 2015, 10, 1353.	0.9	48
143	Chronic obstructive pulmonary disease in the United Kingdom: trends in mortality, morbidity, and smoking. <i>Current Opinion in Pulmonary Medicine</i> , 2002, 8, 95-101.	1.2	47
144	Lung Function, Radiological Findings and Biomarkers of Fibrogenesis in a Cohort of COVID-19 Patients Six Months After Hospital Discharge. <i>Archivos De Bronconeumologia</i> , 2022, 58, 142-149.	0.4	47

#	ARTICLE	IF	CITATIONS
145	Chronic Obstructive Pulmonary Disease with Lung Cancer and/or Cardiovascular Disease. Proceedings of the American Thoracic Society, 2008, 5, 842-847.	3.5	46
146	Conocimientos de la población general sobre la enfermedad pulmonar obstructiva crónica y sus determinantes: situación actual y cambios recientes. Archivos De Bronconeumología, 2012, 48, 308-315.	0.4	45
147	Respiratory infection by <i>Corynebacterium striatum</i> : epidemiological and clinical determinants. New Microbes and New Infections, 2014, 2, 106-114.	0.8	45
148	Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respiratory Research, 2016, 17, 120.	1.4	45
149	COVID-19 mortality rates in the European Union, Switzerland, and the UK: effect of timeliness, lockdown rigidity, and population density. Minerva Medica, 2020, 111, 308-314.	0.3	45
150	Association Between Obstructive Sleep Apnea and Pulmonary Embolism. Mayo Clinic Proceedings, 2013, 88, 579-587.	1.4	44
151	Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1989-1998.e3.	2.0	44
152	Mixed Th2 and non-Th2 inflammatory pattern in the asthma&ndash;COPD overlap: a network approach. International Journal of COPD, 2018, Volume 13, 591-601.	0.9	44
153	Palliative care and prognosis in COPD: a systematic review with a validation cohort. International Journal of COPD, 2017, Volume 12, 1721-1729.	0.9	43
154	Global Alliance for Chronic Disease researchers' statement on multimorbidity. The Lancet Global Health, 2018, 6, e1270-e1271.	2.9	43
155	Finding the Best Thresholds of FEV1 and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study. PLoS ONE, 2014, 9, e89866.	1.1	43
156	New GOLD classification: longitudinal data on group assignment. Respiratory Research, 2014, 15, 3.	1.4	42
157	ACO: Time to move from the description of different phenotypes to the treatable traits. PLoS ONE, 2019, 14, e0210915.	1.1	42
158	Spirometrically-defined restrictive ventilatory defect: population variability and individual determinants. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 21, 187-193.	2.5	41
159	Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD. Archivos De Bronconeumología, 2012, 48, 247-257.	0.4	41
160	Gaps in COPD Guidelines of Low- and Middle-Income Countries. Chest, 2021, 159, 575-584.	0.4	41
161	Effect of the Method of Administration, Mail or Telephone, on the Validity and Reliability of a Respiratory Health Questionnaire. The Spanish Centers of the European Asthma Study. Journal of Clinical Epidemiology, 1998, 51, 875-881.	2.4	39
162	Validation of a Chronic Obstructive Pulmonary Disease screening questionnaire for population surveys. Respiratory Medicine, 2004, 98, 78-83.	1.3	39

#	ARTICLE	IF	CITATIONS
163	Symptoms of asthma, bronchial responsiveness and atopy in immigrants and emigrants in Europe. <i>European Respiratory Journal</i> , 2001, 18, 459-465.	3.1	38
164	Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 1097.e11-1097.e24.	1.2	38
165	Atención médica según el nivel de riesgo y su adecuación a las recomendaciones de la guía española de la enfermedad pulmonar obstructiva crónica (EPOC) (GesEPOC): Estudio EPOCONSUL. <i>Archivos De Bronconeumología</i> , 2018, 54, 270-279.	0.4	38
166	Prognostic assessment in COPD without lung function: the B-AE-D indices. <i>European Respiratory Journal</i> , 2016, 47, 1635-1644.	3.1	37
167	The burden of disease in Spain: Results from the Global Burden of Disease 2016. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 171-190.	0.1	37
168	A multicentre, randomized controlled trial of telehealth for the management of COPD. <i>Respiratory Medicine</i> , 2018, 144, 74-81.	1.3	36
169	Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device. <i>Respiratory Medicine</i> , 2016, 120, 54-63.	1.3	35
170	Underdiagnosis of Chronic Obstructive Pulmonary Disease in Women: Quantification of the Problem, Determinants and Proposed Actions. <i>Archivos De Bronconeumología</i> , 2013, 49, 223-229.	0.4	34
171	OSA Is a Risk Factor for Recurrent VTE. <i>Chest</i> , 2016, 150, 1291-1301.	0.4	34
172	Asthma Visits to Emergency Rooms and Soybean Unloading in the Harbors of Valencia and A Coruna, Spain. <i>American Journal of Epidemiology</i> , 1999, 149, 315-322.	1.6	33
173	A Comprehensive, National Survey of Spirometry in Spain. <i>Chest</i> , 2013, 144, 601-609.	0.4	33
174	Datos epidemiológicos de EPOC en España. <i>Archivos De Bronconeumología</i> , 2007, 43, 2-9.	0.4	32
175	Chronic Obstructive Pulmonary Disease. <i>Medical Clinics of North America</i> , 2012, 96, 671-680.	1.1	32
176	Identification and diversity of multiresistant <i>Corynebacterium striatum</i> clinical isolates by MALDI-TOF mass spectrometry and by a multigene sequencing approach. <i>BMC Microbiology</i> , 2012, 12, 52.	1.3	32
177	Prevalence and Characteristics of Asthma-Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1143-1150.	1.5	32
178	Investigating the Natural History of Lung Function. <i>Chest</i> , 2009, 135, 1330-1341.	0.4	31
179	The General Public's Knowledge of Chronic Obstructive Pulmonary Disease and Its Determinants: Current Situation and Recent Changes. <i>Archivos De Bronconeumología</i> , 2012, 48, 308-315.	0.4	31
180	Asthma insights and reality in the United Arab Emirates. <i>Annals of Thoracic Medicine</i> , 2010, 5, 217.	0.7	30

#	ARTICLE	IF	CITATIONS
181	Medical comorbidity in recurrent versus first-episode depressive patients. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 220-227.	2.2	30
182	Bacterial flora in the sputum and comorbidity in patients with acute exacerbations of COPD. <i>International Journal of COPD</i> , 2015, 10, 2581.	0.9	30
183	Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease. <i>Archivos De Bronconeumologia</i> , 2017, 53, 324-335.	0.4	30
184	Efficacy and costs of telehealth for the management of COPD: the PROMETE II trial. <i>European Respiratory Journal</i> , 2018, 51, 1800354.	3.1	30
185	Nuevo estudio sobre la prevalencia de la EPOC en España: resumen del protocolo EPISCAN II, 10 años después de EPISCAN. <i>Archivos De Bronconeumologia</i> , 2019, 55, 38-47.	0.4	30
186	Tackling second-hand exposure to tobacco smoke and aerosols of electronic cigarettes: the TackSHS project protocol. <i>Gaceta Sanitaria</i> , 2020, 34, 77-82.	0.6	30
187	Prognosis of COPD patients requiring frequent hospitalization: Role of airway infection. <i>Respiratory Medicine</i> , 2010, 104, 840-848.	1.3	29
188	Recent epidemiological trends in tuberculous pleural effusion in Galicia, Spain. <i>European Journal of Internal Medicine</i> , 2012, 23, 727-732.	1.0	29
189	Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry. <i>Respiratory Research</i> , 2019, 20, 127.	1.4	29
190	Use of N-Acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19. <i>Science Progress</i> , 2022, 105, 003685042210745.	1.0	29
191	Inappropriate asthma therapy—a tale of two countries: a parallel population-based cohort study. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16076.	1.1	28
192	Underdiagnosis in COPD: a battle worth fighting. <i>Lancet Respiratory Medicine</i> , 2017, 5, 367-368.	5.2	28
193	Advanced forecasting of SARS-CoV-2-related deaths in Italy, Germany, Spain, and New York State. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1813-1815.	2.7	28
194	Geographical Variations in the Prevalence of COPD in Spain: Relationship to Smoking, Death Rates and other Determining Factors. <i>Archivos De Bronconeumologia</i> , 2010, 46, 522-530.	0.4	27
195	Prevalence of COPD in Abu Dhabi, United Arab Emirates. <i>Respiratory Medicine</i> , 2011, 105, 566-570.	1.3	27
196	Airflow obstruction case finding in community-pharmacies: A novel strategy to reduce COPD underdiagnosis. <i>Respiratory Medicine</i> , 2015, 109, 475-482.	1.3	27
197	Expansion of myeloid-derived suppressor cells in chronic obstructive pulmonary disease and lung cancer: potential link between inflammation and cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1261-1270.	2.0	27
198	Face masks, respiratory patients and COVID-19. <i>European Respiratory Journal</i> , 2020, 56, 2003325.	3.1	27

#	ARTICLE	IF	CITATIONS
199	Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases. Archivos De Bronconeumologia, 2021, 57, 13-20.	0.4	27
200	Prevalence and Determinants of COPD in Spain: EPISCAN II. Archivos De Bronconeumologia, 2021, 57, 61-69.	0.4	27
201	[Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. Archivos De Bronconeumologia, 2022, 58, T69-T81.	0.4	27
202	Comorbidity and short-term prognosis in hospitalised COPD patients: the ESMI study. European Respiratory Journal, 2015, 46, 850-853.	3.1	26
203	Critical review of multimorbidity outcome measures suitable for low-income and middle-income country settings: perspectives from the Global Alliance for Chronic Diseases (GACD) researchers. BMJ Open, 2020, 10, e037079.	0.8	25
204	Exposure to secondhand aerosol of electronic cigarettes in indoor settings in 12 European countries: data from the TackSHS survey. Tobacco Control, 2021, 30, 49-56.	1.8	25
205	Long-term mortality follow-up of the ISOLDE participants: Causes of death during 13 years after trial completion. Respiratory Medicine, 2008, 102, 1468-1472.	1.3	24
206	Increased exhaled breath temperature in subjects with uncontrolled asthma. International Journal of Tuberculosis and Lung Disease, 2013, 17, 969-972.	0.6	24
207	Overdiagnosis of COPD: precise definitions and proposals for improvement. British Journal of General Practice, 2017, 67, 183-184.	0.7	24
208	Prevalencia de enfermedad pulmonar obstructiva cr�nica en 6 aglomerados urbanos de Argentina: el estudio EPOC.AR. Archivos De Bronconeumologia, 2018, 54, 260-269.	0.4	24
209	Causes of death in asthma, COPD and non-respiratory hospitalized patients: a multicentric study. BMC Pulmonary Medicine, 2013, 13, 73.	0.8	23
210	An Intensive Lifestyle Intervention Is an Effective Treatment of Morbid Obesity: The TRAMONTANA Study. A Two-Year Randomized Controlled Clinical Trial. International Journal of Endocrinology, 2015, 2015, 1-11.	0.6	23
211	High D-dimer levels after stopping anticoagulants in pulmonary embolism with sleep apnoea. European Respiratory Journal, 2015, 46, 1691-1700.	3.1	23
212	Altitude and COPD prevalence: analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study. Respiratory Research, 2017, 18, 162.	1.4	23
213	Respiratory symptoms, lung function and use of health services among unemployed young adults in Spain. European Respiratory Journal, 1998, 11, 1363-1368.	3.1	22
214	Risk of asthma in the general Spanish population attributable to specific immunoresponse. Spanish Group of the European Community Respiratory Health Survey. International Journal of Epidemiology, 1999, 28, 728-734.	0.9	22
215	Chronic obstructive pulmonary disease History Assessment in Spain: una valoraci�n multidimensional de la enfermedad pulmonar obstructiva cr�nica. M�todo y organizaci�n del trabajo. Archivos De Bronconeumologia, 2012, 48, 453-459.	0.4	22
216	Differential effects of smoking and COPD upon circulating myeloid derived suppressor cells. Respiratory Medicine, 2013, 107, 1895-1903.	1.3	22

#	ARTICLE	IF	CITATIONS
217	Polypharmacy in patients hospitalised for acute exacerbation of COPD. <i>European Respiratory Journal</i> , 2014, 44, 791-794.	3.1	22
218	Trends of testing for and diagnosis of Î± <sub>1</sub> -antitrypsin deficiency in the UK: more testing is needed. <i>European Respiratory Journal</i> , 2018, 52, 1800360.	3.1	22
219	Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population. <i>Archivos De Bronconeumologia</i> , 2020, 56, 76-83.	0.4	22
220	Survival Among Copd Patients Using Fluticasone/Salmeterol in Combination Versus Other Inhaled Steroids and Bronchodilators Alone. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2007, 4, 127-134.	0.7	21
221	An Epidemiological Overview of Chronic Obstructive Pulmonary Disease: What Can Real-Life Data Tell Us about Disease Management?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, S3-S7.	0.7	21
222	Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. <i>BMC Medicine</i> , 2018, 16, 33.	2.3	21
223	Reversing concepts on COPD irreversibility. <i>European Respiratory Journal</i> , 2008, 31, 695-696.	3.1	20
224	Case-finding of chronic obstructive pulmonary disease with questionnaire, peak flow measurements and spirometry: a cross-sectional study. <i>BMC Research Notes</i> , 2014, 7, 241.	0.6	20
225	Clinical Application of the COPD Assessment Test. <i>Chest</i> , 2014, 146, 111-122.	0.4	20
226	Î³-Adrenergic receptor Trp64Arg polymorphism and increased body mass index in sleep apnoea. <i>European Respiratory Journal</i> , 2007, 30, 743-747.	3.1	19
227	Is spirometry properly used to diagnose COPD? Results from the BOLD study in Salzburg, Austria: a population-based analytical study. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2013, 22, 195-200.	2.5	19
228	Maxillomandibular advancement as the initial treatment of obstructive sleep apnoea: Is the mandibular occlusal plane the key?. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2017, 46, 1363-1371.	0.7	19
229	Sex bias in diagnostic delay in bronchiectasis: An analysis of the Spanish Historical Registry of Bronchiectasis. <i>Chronic Respiratory Disease</i> , 2017, 14, 360-369.	1.0	18
230	Recent lung cancer mortality trends in Europe: effect of national smoke-free legislation strengthening. <i>European Journal of Cancer Prevention</i> , 2018, 27, 296-302.	0.6	18
231	Factors associated with mortality in patients with exacerbation of chronic obstructive pulmonary disease hospitalized in General Medicine departments. <i>Internal and Emergency Medicine</i> , 2011, 6, 47-54.	1.0	17
232	Theophylline again? Reasons for believing. <i>European Respiratory Journal</i> , 2009, 34, 5-6.	3.1	16
233	Mortality from cystic fibrosis in Europe: 1994â€“2010. <i>Pediatric Pulmonology</i> , 2016, 51, 133-142.	1.0	16
234	The most beautiful COPD chart in the world: all together to end COPD!. <i>European Respiratory Journal</i> , 2019, 54, 1902047.	3.1	16



#	ARTICLE	IF	CITATIONS
235	Secondhand smoke exposure in outdoor children's playgrounds in 11 European countries. <i>Environment International</i> , 2021, 149, 105775.	4.8	16
236	Nefer, Sinuhe and clinical research assessing post COVID-19 condition. <i>European Respiratory Journal</i> , 2021, 57, 2004423.	3.1	16
237	[Translated article] Spanish COPD Guidelines (GesEPOC) 2021 Update. Diagnosis and Treatment of COPD Exacerbation Syndrome. <i>Archivos De Bronconeumologia</i> , 2022, 58, T159-T170.	0.4	16
238	Long term outcome of soybean epidemic asthma after an allergen reduction intervention. <i>Thorax</i> , 1999, 54, 670-674.	2.7	15
239	Dynamic hyperinflation and pulmonary inflammation: a potentially relevant relationship?. <i>European Respiratory Review</i> , 2006, 15, 68-71.	3.0	15
240	Set-up and pilot of a population cohort for the study of the natural history of COPD and OSA: the PULSAIB study. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2010, 19, 140-147.	2.5	15
241	The European Respiratory Journal makes COPD a priority. <i>European Respiratory Journal</i> , 2011, 38, 999-1001.	3.1	15
242	Cambios interregionales en la realización e interpretación de las espirometrías en España: estudio 3E. <i>Archivos De Bronconeumologia</i> , 2014, 50, 475-483.	0.4	15
243	Adecuación del nivel de intervención en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) según la estratificación de riesgo propuesta por la Guía española de la EPOC (GesEPOC) versión 2017. <i>Archivos De Bronconeumologia</i> , 2020, 56, 183-185.	0.4	15
244	Burden of disease from breast cancer attributable to smoking and second-hand smoke exposure in Europe. <i>International Journal of Cancer</i> , 2020, 147, 2387-2393.	2.3	15
245	Burden of disease from second-hand tobacco smoke exposure at home among adults from European Union countries in 2017: an analysis using a review of recent meta-analyses. <i>Preventive Medicine</i> , 2021, 145, 106412.	1.6	15
246	Knowledge and perceptions of asthma in Zambia: a cross-sectional survey. <i>BMC Pulmonary Medicine</i> , 2016, 16, 33.	0.8	14
247	Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: a multi-level, cross-sectional analysis of the EPOCONSUL study. <i>Respiratory Research</i> , 2017, 18, 200.	1.4	14
248	Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study. <i>PLoS ONE</i> , 2018, 13, e0198777.	1.1	14
249	La EPOC en España al inicio de una nueva década. <i>Archivos De Bronconeumologia</i> , 2021, 57, 1-2.	0.4	14
250	The ERS Research Agency: the beginning. <i>European Respiratory Journal</i> , 2016, 47, 1017-1023.	3.1	13
251	Determinants of medical prescriptions for COPD care: an analysis of the EPOCONSUL clinical audit. <i>International Journal of COPD</i> , 2018, Volume 13, 2279-2288.	0.9	13
252	Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. <i>Archivos De Bronconeumologia</i> , 2021, 58, T69-T69.	0.4	13



#	ARTICLE	IF	CITATIONS
253	Hospital Epidemics Tracker (HEpiTracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e21653.	1.2	13
254	Unravelling data for rapid evidence-based response to COVID-19: a summary of the unCoVer protocol. <i>BMJ Open</i> , 2021, 11, e055630.	0.8	13
255	One year weight loss in the TRAMOMTANA study. A randomized controlled trial. <i>Clinical Endocrinology</i> , 2013, 79, 791-799.	1.2	12
256	The evaluation of a remote support program on quality of life and evolution of disease in COPD patients with frequent exacerbations. <i>BMC Pulmonary Medicine</i> , 2016, 16, 140.	0.8	12
257	Effects of simvastatin in chronic obstructive pulmonary disease: Results of a pilot, randomized, placebo-controlled clinical trial. <i>Contemporary Clinical Trials Communications</i> , 2016, 2, 91-96.	0.5	12
258	Temporal transitions in COPD severity stages within the GOLD 2017 classification system. <i>Respiratory Medicine</i> , 2018, 142, 81-85.	1.3	12
259	Triple therapy for COPD: a crude analysis from a systematic review of the evidence. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661988552.	1.0	12
260	Burden of respiratory disease attributable to secondhand smoke exposure at home in children in Spain (2015). <i>Preventive Medicine</i> , 2019, 123, 34-40.	1.6	12
261	Obstructive sleep apnea is associated with worse clinical&#x2013;radiological risk scores of pulmonary embolism. <i>Journal of Sleep Research</i> , 2020, 29, e12871.	1.7	12
262	Obstructive sleep apnea in adults with Down syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2020, 182, 2832-2840.	0.7	12
263	Medical event profiling of COPD patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 547-555.	0.9	11
264	Medical Care According to Risk Level and Adaptation to Spanish COPD Guidelines (GesEPOC): The Epoconsul Study. <i>Archivos De Bronconeumologia</i> , 2018, 54, 270-279.	0.4	11
265	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 234-243.	1.9	11
266	Observational Studies of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Misconstrued Immortal Time Bias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 464a-465.	2.5	10
267	Frequency of Multi-dimensional COPD Indices and Relation &#x2013;with Disease Activity Markers. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 436-443.	0.7	10
268	10 Years After EPISCAN: A New Study on the Prevalence of COPD in Spain&#x2013;A Summary of the EPISCAN II Protocol. <i>Archivos De Bronconeumologia</i> , 2019, 55, 38-47.	0.4	10
269	Burden of disease from exposure to secondhand smoke in children in Europe. <i>Pediatric Research</i> , 2021, 90, 216-222.	1.1	10
270	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. <i>ERJ Open Research</i> , 2020, 6, 00253-2020.	1.1	10

#	ARTICLE	IF	CITATIONS
271	Impact of Obstructive Sleep Apnea on Gestational Diabetes Mellitus. Archivos De Bronconeumologia, 2022, 58, 219-227.	0.4	10
272	Lung function changes in patients with chronic obstructive pulmonary disease (COPD) and asthma exposed to secondhand smoke in outdoor areas. Journal of Asthma, 2021, 58, 1169-1175.	0.9	10
273	Small airway dysfunction in smokers with stable ischemic heart disease. PLoS ONE, 2017, 12, e0182858.	1.1	10
274	Determinants of blood eosinophil levels in the general population and patients with COPD: a population-based, epidemiological study. Respiratory Research, 2022, 23, 49.	1.4	10
275	Inter-Regional Changes in the Performance and Interpretation of Spirometry in Spain: 3E Study. Archivos De Bronconeumologia, 2014, 50, 475-483.	0.4	9
276	On Doctors and Their Operas. Chest, 2018, 154, 409-415.	0.4	9
277	Geographical Distribution of COPD Prevalence in the Americas. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 317-325.	0.7	9
278	Secondhand smoke exposure and other signs of tobacco consumption at outdoor entrances of primary schools in 11 European countries. Science of the Total Environment, 2020, 743, 140743.	3.9	9
279	Association study of proposed candidate genes/regions in a population of Spanish asthmatics. European Journal of Epidemiology, 2000, 16, 745-750.	2.5	8
280	Symptoms of asthma, bronchial responsiveness and atopy in immigrants and emigrants in Europe. European Respiratory Journal, 2002, 19, 980-983.	3.1	8
281	Facial edema associated with thyroid autoimmunity. Allergologia Et Immunopathologia, 2002, 30, 47-50.	1.0	8
282	The of COPD: or balancing repair (yang) and inflammation (yin). European Respiratory Journal, 2008, 32, 1426-1427.	3.1	8
283	ERJ peer reviewers: does this pillar of the Journal's quality need help?. European Respiratory Journal, 2011, 38, 251-252.	3.1	8
284	A BOLD statement on how to case-find moderate/severe COPD. European Respiratory Journal, 2013, 41, 503-504.	3.1	8
285	Differences in the use of spirometry between rural and urban primary care centers in Spain. International Journal of COPD, 2015, 10, 1633.	0.9	8
286	Medicina planetaria respiratoria. Archivos De Bronconeumologia, 2017, 53, 297-299.	0.4	8
287	Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation. Respiratory Medicine, 2017, 129, 199-206.	1.3	8
288	Prevalence of COPD in 6 Urban Clusters in Argentina: The EPOC.AR Study. Archivos De Bronconeumologia, 2018, 54, 260-269.	0.4	8

#	ARTICLE	IF	CITATIONS
289	Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2020, 162, 102186.	1.0	8
290	Small airways and early origins of COPD: pathobiological and epidemiological considerations. <i>European Respiratory Journal</i> , 2020, 55, 1902457.	3.1	8
291	Work absence in patients with asthma and/or COPD: a population-based study. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 9.	1.1	8
292	Sobre la nueva condición post COVID-19. <i>Archivos De Bronconeumología</i> , 2021, 57, 735-735.	0.4	8
293	On the new post COVID-19 condition. <i>Archivos De Bronconeumología</i> , 2021, 57, 735-736.	0.4	8
294	Towards a universal understanding of post COVID-19 condition. <i>Bulletin of the World Health Organization</i> , 2021, 99, 901-903.	1.5	8
295	International cross-sectional and longitudinal assessment on asthma control in European adult patients - the LIAISON study protocol. <i>BMC Pulmonary Medicine</i> , 2013, 13, 18.	0.8	7
296	Predictors of cost-effectiveness of selected COPD treatments in primary care: UNLOCK study protocol. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 15051.	1.1	7
297	Multiple Score Comparison: a network meta-analysis approach to comparison and external validation of prognostic scores. <i>BMC Medical Research Methodology</i> , 2017, 17, 172.	1.4	7
298	The evolution of COPD species; or, something is changing for good in COPD. <i>European Respiratory Journal</i> , 2019, 53, 1900762.	3.1	7
299	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CiAplus Cohort Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 8-17.	0.7	7
300	Desaturations During 6-Minute Walk Test and Predicting Nocturnal Desaturations in Adult Subjects With Cystic Fibrosis. <i>Respiratory Care</i> , 2019, 64, 48-54.	0.8	7
301	Humanistic Epidemiology: Love in the time of cholera, COVID-19 and other outbreaks. <i>European Journal of Epidemiology</i> , 2020, 35, 321-324.	2.5	7
302	Face mask exemptions, psychiatric patients, and COVID-19. <i>European Psychiatry</i> , 2021, 64, e6.	0.1	7
303	Improving paediatric asthma care in Zambia. <i>Bulletin of the World Health Organization</i> , 2015, 93, 732-736.	1.5	7
304	Forecasting COVID-19 Infection Trends and New Hospital Admissions in Spain due to SARS-CoV-2 Variant of Concern Omicron. <i>Archivos De Bronconeumología</i> , 2022, 58, 200-202.	0.4	7
305	Incidental findings from lung CT scans: Implications for research. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2011, 55, 20-25.	0.9	6
306	The role of air pollution in COPD and implications for therapy. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 849-859.	1.0	6

#	ARTICLE	IF	CITATIONS
307	Ageing lungs and very elderly COPD: anytime and anywhere. <i>European Respiratory Journal</i> , 2016, 47, 379-381.	3.1	6
308	Changes and Clinical Consequences of Smoking Cessation in Patients With COPD. <i>Chest</i> , 2018, 154, 274-285.	0.4	6
309	Inhaled corticosteroids and pneumonia mortality in COPD patients. <i>European Respiratory Journal</i> , 2019, 54, 1901035.	3.1	6
310	New evidence on the chemoprevention of inhaled steroids and the risk of lung cancer in COPD. <i>European Respiratory Journal</i> , 2019, 53, 1900717.	3.1	6
311	Non-smokers' and smokers' support for smoke-free legislation in 14 indoor and outdoor settings across 12 European countries. <i>Environmental Research</i> , 2022, 204, 112224.	3.7	6
312	Electronic Cigarette Use in 12 European Countries: Results From the TackSHS Survey. <i>Journal of Epidemiology</i> , 2023, 33, 276-284.	1.1	6
313	The GOLD Rush. <i>Thorax</i> , 2013, 68, 902-903.	2.7	5
314	Determinants of use of the bronchodilator test in primary and secondary care: results of a national survey in Spain. <i>Clinical Respiratory Journal</i> , 2016, 10, 217-222.	0.6	5
315	Biologics may have a beneficial effect in asthma patients with COVID-19. <i>European Respiratory Journal</i> , 2021, 58, 2101076.	3.1	5
316	Secondhand smoke exposure assessment in outdoor hospitality venues across 11 European countries. <i>Environmental Research</i> , 2021, 200, 111355.	3.7	5
317	An Euler Proportional Venn Diagram of Obstructive Lung Disease. <i>Archivos De Bronconeumologia</i> , 2022, 58, 627-628.	0.4	5
318	Remember elephants and icebergs... "Your lung function should be here, but it is there!". <i>European Respiratory Journal</i> , 2009, 33, 715-716.	3.1	4
319	Chronic Obstructive Pulmonary Disease History Assessment in Spain: A Multidimensional Chronic Obstructive Pulmonary Disease Evaluation. Study Methods and Organization. <i>Archivos De Bronconeumologia</i> , 2012, 48, 453-459.	0.4	4
320	Sleep apnea syndrome and patent foramen ovale: a dangerous association in ischemic stroke?. <i>Sleep Medicine</i> , 2016, 25, 29-33.	0.8	4
321	Bronchiectasis and asthma. <i>European Respiratory Journal</i> , 2016, 47, 1597-1600.	3.1	4
322	$\alpha$ 1-Antitrypsin deficiency: count me in please!. <i>European Respiratory Journal</i> , 2017, 49, 1601941.	3.1	4
323	Assessing the clinical practice in specialized outpatient clinics for chronic obstructive pulmonary disease: Analysis of the EPOCONSUL clinical audit. <i>PLoS ONE</i> , 2019, 14, e0211732.	1.1	4
324	Connected real-life research, a pillar of P4 medicine. <i>European Respiratory Journal</i> , 2020, 55, 1902287.	3.1	4

#	ARTICLE	IF	CITATIONS
325	Medicina, Epidemiología y Humanismo antes y después de la COVID-19. Revista Clínica Española, 2020, 220, 503-506.	0.2	4
326	Inhaled antibiotics for treatment of adults with non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis. European Journal of Internal Medicine, 2021, 90, 77-88.	1.0	4
327	Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis. Antibiotics, 2022, 11, 275.	1.5	4
328	Description of extreme longevity in the Balearic Islands: Exploring a potential Blue Zone in Menorca, Spain. Geriatrics and Gerontology International, 2014, 14, 620-627.	0.7	3
329	ESCAPEing from bad-quality air: a cleaner air, from Europe to elsewhere. European Respiratory Journal, 2015, 45, 11-13.	3.1	3
330	Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population. Archivos De Bronconeumología, 2020, 56, 76-83.	0.4	3
331	Your racing horses will help you to quit: a lesson for COPD and $\alpha$ 1-antitrypsin deficiency research. European Respiratory Journal, 2009, 33, 1244-1246.	3.1	2
332	No more hic sunt dracones: Portugal is in the COPD map. Revista Portuguesa De Pneumologia, 2013, 19, 86-87.	0.7	2
333	Getting risks right on inhaled corticosteroids and adrenal insufficiency. European Respiratory Journal, 2013, 42, 9-11.	3.1	2
334	Global Lung Function Initiative Equations: The Legacy Starts. Respiration, 2016, 92, 131-133.	1.2	2
335	Respiratory Planetary Medicine. Archivos De Bronconeumología, 2017, 53, 297-299.	0.4	2
336	On Don Quixote and pink puffers: multi-organ loss of tissue COPD. European Respiratory Journal, 2018, 51, 1702560.	3.1	2
337	Brighter than GOLD. Lancet Respiratory Medicine, the, 2018, 6, 165-166.	5.2	2
338	Adjusting the Level of Intervention in Patients with Chronic Obstructive Pulmonary Disease According to the Risk Stratification Proposed by the Spanish COPD Guidelines (GesEPOC) Version 2017. Archivos De Bronconeumología, 2020, 56, 183-185.	0.4	2
339	Sobre la enfermedad pulmonar obstructiva crónica y el big data. Archivos De Bronconeumología, 2021, 57, 144.	0.4	2
340	Cabbage and COVID-19. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 966-967.	2.7	2
341	[Translated article] COVID-19 in Youth and the Fifth Wave. Archivos De Bronconeumología, 2022, 58, T213-T214.	0.4	2
342	Eppur si muove, or COPD treatment success and inflammation. European Respiratory Journal, 2007, 30, 409-410.	3.1	1

#	ARTICLE	IF	CITATIONS
343	An Integrated therapeutic approach: do COPD comorbidities justify it?. Revista Portuguesa De Pneumologia, 2014, 20, 3-4.	0.7	1
344	A golden goal in 2010, and another GOLD in 2014 in primary care, or vice versa. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2014, 23, 5-6.	2.5	1
345	Global Tuberculosis Elimination: The Relevance of Trend Surveillance in Mexico and Beyond. Archivos De Bronconeumologia, 2015, 51, 3-4.	0.4	1
346	Smoking cessation and COPD: further evidence is more necessary than ever. European Respiratory Journal, 2017, 49, 1700466.	3.1	1
347	Challenges in interpreting trends in testing for $\alpha$ 1-antitrypsin deficiency in COPD patients from UK primary care. European Respiratory Journal, 2018, 52, 1802064.	3.1	1
348	Reply to COPD diagnosis in EPI-SCAN II. Archivos De Bronconeumologia, 2021, 57, 235.	0.4	1
349	Authors' Reply to: Minimizing Selection and Classification Biases Comment on "Clinical Characteristics and Prognostic Factors for Intensive Care Unit Admission of Patients With COVID-19: Retrospective Study Using Machine Learning and Natural Language Processing". Journal of Medical Internet Research, 2021, 23, e29405.	2.1	1
350	Asthma and COPD: Just Old Friends or Relatives?. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 870-871.	2.5	1
351	Critical appraisal of international adult bronchiectasis guidelines using the AGREE II tool. European Journal of Internal Medicine, 2022, , .	1.0	1
352	Epidemiology of COVID-19: global spread, risk factors for disease incidence, severity and mortality. , 2021, , 14-27.		1
353	Sing out for COPD!. European Respiratory Journal, 2022, 59, 2102961.	3.1	1
354	Mortality in Lung Cancer and COPD. Archivos De Bronconeumologia, 2010, 46, 281.	0.4	0
355	Geographic variability in COPD prevalence [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 709-710.	0.6	0
356	Formación continuada en espirometrías: una luz en el camino. Archivos De Bronconeumologia, 2013, 49, 369-370.	0.4	0
357	Continuing Education in Spirometry: A Light Along the Way. Archivos De Bronconeumologia, 2013, 49, 369-370.	0.4	0
358	In Response to: Martínez-Velilla N. GesEPOC Guidelines and Elderly Patients. Archivos De Bronconeumologia, 2014, 50, 155.	0.4	0
359	Respuesta a: Martínez-Velilla N. Guía GesEPOC y pacientes ancianos. Archivos De Bronconeumologia, 2014, 50, 155.	0.4	0
360	Response. Chest, 2014, 145, 1172-1173.	0.4	0

#	ARTICLE	IF	CITATIONS
361	What if . . . the National Heart, Lung, and Blood Institute Considers Tobacco?. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1471-1471.	2.5	0
362	Eliminaci3n mundial de la tuberculosis: la importancia de vigilar las tendencias en M4jico y otros lugares. Archivos De Bronconeumologia, 2015, 51, 3-4.	0.4	0
363	Quality of Spirometric Data in Spain: The 3E Study. Archivos De Bronconeumologia, 2016, 52, 109.	0.4	0
364	Calidad de los datos de las espirometr4as en Espa4a: estudio 3E. Archivos De Bronconeumologia, 2016, 52, 109.	0.4	0
365	Response. Chest, 2017, 151, 515-516.	0.4	0
366	Response regarding the methodological approach used to calculate the burden of respiratory disease attributable to secondhand smoke exposure in children in Spain for the year 2015. Preventive Medicine, 2019, 129, 105723.	1.6	0
367	A "Parasite" in bronchiectasis and COPD research. Annals of Translational Medicine, 2020, 8, 426-426.	0.7	0
368	Chronic Obstructive Pulmonary Disease and Big Data. Archivos De Bronconeumologia, 2021, 57, 144.	0.4	0
369	Respuesta a "El diagn3stico de la EPOC en EPI-SCAN II". Archivos De Bronconeumologia, 2021, 57, 235.	0.4	0
370	Impacto de la COVID-19 en la poblaci3n latinoamericana en Espa4a durante la primera y segunda ola. Medicina Cl4nica, 2021, 157, 496-497.	0.3	0
371	Reply: Lung Function Abnormalities in Smokers with Ischemic Heart Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1537-1538.	2.5	0
372	Epidemiological aspects of cardiovascular and respiratory diseases. , 2020, , 1-11.		0
373	Impact of COVID-19 on the Latin American population in Spain during the first and second waves. Medicina Cl4nica (English Edition), 2021, 157, 496-497.	0.1	0
374	Screening and case finding. , 0, , 1-25.		0
375	Forecasting COVID-19 infection trends and hospitalizations in Italy due to SARS-CoV-2 variant of concern Omicron. Minerva Respiratory Medicine, 2022, 61, .	0.1	0